What is Bio-Rad Laboratories Inc's share price today?
Bio-Rad Laboratories Inc (BIO.B) share price today is $368.07 as of October 23, 2026 at 8:37 PM IST. The stock touched a day high of $368.77 and a day low of $368.07.What exchange does Bio-Rad Laboratories Inc stock trade on, and under what ticker symbol?
Bio-Rad Laboratories Inc stock trades on NYSE under the ticker symbol BIO.B.What is Bio-Rad Laboratories Inc's market capitalization?
Bio-Rad Laboratories Inc's market capitalization is $9.74B as of October 23, 2026 at 8:37 PM IST.What is Bio-Rad Laboratories Inc's price-to-earnings (P/E) ratio?
Bio-Rad Laboratories Inc's price-to-earnings (P/E) ratio is 46.15 as of October 23, 2026.What is Bio-Rad Laboratories Inc's price-to-book (P/B) ratio?
Bio-Rad Laboratories Inc's price-to-book (P/B) ratio is 1.36 as of October 23, 2026.Can Indian investors buy Bio-Rad Laboratories Inc shares?
Yes, You can buy Bio-Rad Laboratories Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Bio-Rad Laboratories Inc shares from India?
Indian investors can buy Bio-Rad Laboratories Inc shares in three steps: 1. Search Bio-Rad Laboratories Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Bio-Rad Laboratories Inc shares for Indian investors?
Since Bio-Rad Laboratories Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Bio-Rad Laboratories Inc shares via Tickertape?
Indian investors can start investing in Bio-Rad Laboratories Inc (BIO.B) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0271 shares at the current price of $368.07.
$
₹
$368.07—% (+368.07)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
46.15
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
1.36
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$7.89
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
1.20
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
8.59%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on consolidated analysts reports
Buy, Sell and Hold recommendations are not available
Price Upside
—
Earnings Growth
—
Rev. Growth
-0.53%
Company Profile
Company Profile
P/E Ratio
36.60
36.60
1Y Return
17.81%
17.81%
Buy Reco %
85.71
85.71
P/E Ratio
34.11
34.11
1Y Return
17.92%
17.92%
Buy Reco %
68.18
68.18
P/E Ratio
34.64
34.64
1Y Return
27.03%
27.03%
Buy Reco %
86.36
86.36
P/E Ratio
112.12
112.12
1Y Return
27.55%
27.55%
Buy Reco %
75.00
75.00
ILMN
P/E Ratio
52.77
52.77
1Y Return
169.5%
169.5%
Buy Reco %
52.38
52.38
Forecast
Forecast
Price
Revenue
Earnings
Revenue Forecast
Revenue Forecast
2025
Current$2.58Baseline
Forecast for Dec 2026
High$2.59+0.43%
Average$2.56-0.53%
Low$2.53-2%
All values in $ Billion
2025
Current$2.58Baseline
Forecast for Dec 2026
High$2.59+0.43%
Average$2.56-0.53%
Low$2.53-2%
All values in $ Billion
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.61 | 0.63 | 0.64 | 0.66 | 0.58 | 0.65 | 0.65 | 0.69 | 0.59 | 0.65 |
| Gross Profit | 0.32 | 0.35 | 0.35 | 0.34 | 0.30 | 0.34 | 0.34 | 0.34 | 0.30 | 0.34 |
| Net Income | 0.38 | -2.16 | 0.65 | -0.71 | 0.06 | 0.31 | -0.34 | 0.72 | -0.52 | 0.37 |
| Net Profit Margin | 62.85% | -339.16% | 100.52% | -107.23% | 10.93% | 48.77% | -52.35% | 103.86% | -89.02% | 57.05% |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareMedical Devices
HealthcareMedical Devices
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Bio-Rad Laboratories Inc | 46.15 | 1.36 | 1.20 |
| Thermo Fisher Scientific Inc | 36.60 | 4.66 | 1.98 |
| Agilent Technologies Inc | 34.11 | 6.33 | 1.36 |
Price Comparison
Price Comparison
Compare BIO.B with any stock or ETFCompare BIO.B with any stock or ETF
Comparing from
BIO.B
TMO
A
The next fiscal year's mean estimate implies -0.53% growth, versus a trailing 3-year CAGR of -2.68%.